维尔达格利普丁与甲福明对2型糖尿病患者肝肥胖症的影响:一项随机对照试验
Asmaa S Mohamed1, Hosam M Ahmad2, Mohammed A Sharawy3
1Clinical Pharmacy and Pharmacy Practice Department, Faculty of Pharmacy, Port said University, Port said, Egypt. Asmaa.Mohamed@pharm.psu.edu.eg.
BMC pharmacology & toxicology
|December 13, 2024
概括
维达格利普丁和美特福林都能改善血糖控制,并减少2型糖尿病患者肝硬化症. 甲胺显示体重增加和BMI降低,但这两种药物都有效降低了肝硬化.
科学领域:
- 内分泌学 在内分泌学.
- 代谢疾病 代谢疾病
- 药理学 药理学是指药理学的学科.
背景情况:
- 2型糖尿病 (T2D) 与肝硬化症 (HS) 的风险增加有关.
- 抗糖尿病药物可能会影响HS的发展和治疗.
- 这项研究评估了新诊断T2D患者的HS的vildagliptin和metformin.
研究的目的:
- 为了比较vildagliptin与甲福明在治疗T2D肝硬化症中的疗效.
- 评估这些药物对血糖控制,身体成分和HS标志物的影响.
主要方法:
- 246名新诊断的T2D患者被随机分配给vildagliptin或metformin.
- 治疗持续时间为6个月,定期进行临床和生化评估.
- 肝硬化指数 (HSI) 和超声波分级用于评估肝硬化.
主要成果:
- 两组都显示出血糖控制 (FBG,HbA1c) 和HS标志物 (HSI,超声波) 的显著改善.
- 与vildagliptin相比,甲福明导致体重和BMI的减少更大.
- 通过超声波在HS改善方面没有显著差异;脂质配置文件是强大的HS预测器.
结论:
- 维尔达格利普丁和美特福明有效地改善了血糖控制,并减少了T2D患者的肝硬化症.
- 甲胺对体重和BMI的减轻产生了更大的影响.
- 总胆固醇和LDL水平被确定为肝硬化症的关键预测因素.
相关概念视频
Oral Hypoglycemic Agents: Biguanides and Glitazones
168
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
168
Dipeptidyl Peptidase 4 Inhibitors
167
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
167
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
155
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
155
Glucagon-like Receptor Agonists
297
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
297
Diabetes Mellitus: Type 2 and Gestational
2.2K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.2K
Oral Hypoglycemic Agents: Glinides
136
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
136


